Baxter Bioscience News Today

GE HealthCare , a leading global precision care innovator, has named James Jay” Saccaro as vice president and chief financial officer , succeeding Helmut Zodl who is remaining with the Company... | May 9, 2023

Our lead drug candidate, obefazimod, has generated promising results in Phase IIa and Phase IIb clinical trials for the treatment of ulcerative colitis, a chronic inflammatory bowel disease, and in a Phase IIa clinical trial in rheumatoid arthritis.

The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting , to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev... | March 30, 2023

The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A.The approval applies to use of the factor VIII replacement therapy as routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment for control of bleeds, and for perioperative management of bleeding. Efanesoctocog alfa (Altuviiio; Bioverativ Therapeutics, Sanofi) is not

PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas - read this article along with other careers information, tips and advice on BioSpace

WARREN, N.J.--(BUSINESS WIRE)--Apr 5, 2022--

The three top executives from Abivax SA (OTCMKTS:AAVXF) explain the development of the ulcerative colitis treatment.

10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM ... | March 7, 2022

-Wound & Tissue Care industry associations -Product managers, Wound & Tissue Care industry administrator, C-level executives of the industries -Market Research and consulting firms Key questions answered in the report What will the market size and growth rate be in 2026? What segment or region will drive or lead market growth and what are the reasons? How will market drivers, constraints and future opportunities affect market dynamics and subsequent analysis of relevant trends? What key strateg...

Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls Ms. Maldonado to Oversee Manufacturing Development of Codagenixs Vaccines as Clinical Trials for COVID-19, RSV and Flu Progress News provided by Share this article Share this article FARMINGDALE, N.Y., April 14, 2021 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the appointment of biotech industry veter...